Securities Report — FY2025
What Pharmarise Holdings Corporation reported for the period from 2025-06-01 to 2026-05-31.
Filed 2026-08-20View the original on EDINET
How much it says
74Detailed
What moved here
32named for the first time
Its own wording
48terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the consolidated fiscal year, the Group expanded and integrated its prescription pharmacy business through M&A and new store openings, increasing revenue and operating profit and returning net income attributable to owners of the parent to profitability. It also continued initiatives including risk management for personal-information protection and cybersecurity, as well as responses to medical DX.
Komori's summary of this document, not the document's own words.74Detailed
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 38 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
96
Very detailed
91
Very detailed
100
Very detailed
75
Very detailed
75
Very detailed
41
Thin
37
Thin
100
Very detailed
60
Detailed
55
Typical
50
Typical
R&D spend10百万円Money spent making new things.
Cash left over13億円Cash from the business, less what went into equipment.
Spent on equipment8億円Plants, machines — things meant to last.
Employees2,031Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.